SCHEMBL6864347

SCHEMBL6864347

CC(C)N(c1ccc(Cl)cc1OCc1ccc(C(=O)O)cc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.52
PTGER1 P34995 3/20 0.50
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
RXRA P19793 5/20 0.48
RXRB P28702 4/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 4/20 0.47
TAS2R14 Q9NYV8 3/20 0.47
MEN1 O00255 2/20 0.47
CXCR3 P49682 1/20 0.47
RXRG P48443 3/20 0.46
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
NR4A2 P43354 1/20 0.44
CYP2C9 P11712 1/20 0.44
LMNA P02545 1/20 0.44
PSMD14 O00487 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1138751 0.92 MRGPRX4 (0.55) MRGPRX4PTGER1RXRARXRBHPGD
SCHEMBL6860607 0.91 MAPT (0.47) MRGPRX4KEAP1NFE2L2HPGDKMT2A
SCHEMBL27490796 0.90 PSEN1 (0.47) PTGER1KEAP1NFE2L2
SCHEMBL6861411 0.89 NR4A2 (0.48) MRGPRX4KEAP1NFE2L2RXRARXRB
SCHEMBL6862672 0.89 KEAP1 (0.49) KEAP1NFE2L2RXRARXRBHPGD
SCHEMBL6863017 0.89 KEAP1 (0.56) PTGER1KEAP1NFE2L2RXRARXRB
SCHEMBL6861681 0.89 KEAP1 (0.56) KEAP1NFE2L2RXRARXRBHPGD
SCHEMBL6860508 0.88 NR1H4 (0.53) MRGPRX4PTGER1KEAP1NFE2L2RXRA
SCHEMBL6863635 0.88 RXRA (0.50) KEAP1NFE2L2RXRARXRBHPGD
SCHEMBL6862426 0.88 MRGPRX4 (0.54) MRGPRX4PTGER1RXRARXRBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN claimed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US claimed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN claimed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP claimed
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN disclosed
US-6790866-B2 SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY ONO PHARMACEUTICAL CO., LTD. (JP) 2004-09-14 US disclosed
US-6448290-B1 PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-10 US disclosed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN disclosed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity CNR1, HCAR1, HCAR2 MRGPRX4 361/4885PTGER1 7/4885KEAP1 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.